The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation
Abstract
Sirolimus (SRL) is a mammalian target of rapamycin inhibitor that, in contrast to cyclosporine (CsA), has been shown to inhibit rather than promote cancers in experimental models. At 3 mo +/- 2 wk after renal transplantation, 430 of 525 enrolled patients were randomly assigned to remain on SRL-CsA-steroids (ST) or to have CsA withdrawn and SRL troughs increased two-fold (SRL-ST). Median times to first skin and nonskin malignancies were compared between treatments using a survival analysis. Mean annualized rates of skin malignancy were calculated, and the relative risk was determined using a Poisson model. Malignancy-free survival rates for nonskin malignancies were compared using Kaplan-Meier estimates and the log-rank test. At 5 yr, the median time to a first skin carcinoma was delayed (491 versus 1126 d; log-rank test, P = 0.007), and the risk for an event was significantly lower with SRL-ST therapy (relative risk SRL-ST to SRL-CsA-ST 0.346; 95% confidence interval 0.227 to 0.526; P < 0.001, intention-to-treat analysis). The relative risks for both basal and squamous cell carcinomas were significantly reduced. Kaplan-Meier estimates of nonskin cancer were 9.6 versus 4.0% (SRL-CsA-ST versus SRL-ST; P = 0.032, intention-to-treat analysis). Nonskin cancers included those of the lung, larynx, oropharynx, kidney, gastrointestinal tract, prostate, breast, thyroid, and cervix as well as glioma, liposarcoma, astrocytoma, leukemia, lymphoma, and Kaposi's sarcoma. Patients who received SRL-based, calcineurin inhibitor-free therapy after CsA withdrawal at month 3 had a reduced incidence of both skin and nonskin malignancies at 5 yr after renal transplantation compared with those who received SRL therapy combined with CsA. Longer follow-up and additional trials are needed to confirm these promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skin cancers after organ transplantation
Euvrard, S., Kanitakis, J., & Claudy, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022137 · Cited by 1,575
Cyclosporine induces cancer progression by a cell-autonomous mechanism
Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., & Suthanthiran, M. (1999) · Nature · doi:10.1038/17401 · Cited by 1,149
Cancer after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D. T., & Wang, C. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00450.x · Cited by 1,071
Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042831 · Cited by 990
Self-citationSkin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management
Berg, D., & Otley, C. C. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.125579 · Cited by 723
Kauffman, H. M., Cherikh, W. S., Cheng, Y., Hanto, D. W., & Kahan, B. D. (2005) · Transplantation · doi:10.1097/01.tp.0000184006.43152.8d · Cited by 621
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Johnson, R. W. G., Kreis, H., Oberbauer, R., Brattstrom, C., Claesson, K., & Eris, J. (2001) · Transplantation · doi:10.1097/00007890-200109150-00007 · Cited by 433
Self-citationPRO- AND ANTI-CANCER EFFECTS OF IMMUNOSUPPRESSIVE AGENTS USED IN ORGAN TRANSPLANTATION
Guba, M., Graeb, C., Jauch, K.-W., & Geissler, E. K. (2004) · Transplantation · doi:10.1097/01.tp.0000120181.89206.54 · Cited by 360
Conversion to sirolimus: a successful treatment for posttransplantation Kaposi???s sarcoma12
Campistol, J. M., Gutierrez-Dalmau, A., & Torregrosa, J. V. (2004) · Transplantation · doi:10.1097/01.tp.0000115344.18025.0b · Cited by 261
Self-citationOberbauer, R., Segoloni, G., Campistol, J. M., Kreis, H., Mota, A., Lawen, J., Russ, G., Grinyo, J. M., Stallone, G., Hartmann, A., et al. (2005) · Transplant International · doi:10.1111/j.1432-2277.2004.00052.x · Cited by 225
Self-citationLong-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine Withdrawal
Kreis, H., Oberbauer, R., Campistol, J. M., Mathew, T., Daloze, P., Schena, F. P., Burke, J. T., Brault, Y., Gioud-Paquet, M., Scarola, J. A., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000113248.59077.76 · Cited by 225
Self-citationKoehl, G. E., Andrassy, J., Guba, M., Richter, S., Kroemer, A., Scherer, M. N., Steinbauer, M., Graeb, C., Schlitt, H. J., Jauch, K.-W., et al. (2004) · Transplantation · doi:10.1097/00007890-200405150-00002 · Cited by 222
RAPAMYCIN, A POTENT IMMUNOSUPPRESSIVE DRUG, CAUSES PROGRAMMED CELL DEATH IN B LYMPHOMA CELLS
Muthukkumar, S., Ramesh, T., & Bondada, S. (1995) · Transplantation · doi:10.1097/00007890-199508000-00010 · Cited by 142
RISK OF NONMELANOMA SKIN CANCER IN ITALIAN ORGAN TRANSPLANT RECIPIENTS. A REGISTRY-BASED STUDY
Naldi, L., Fortina, A. B., Lovati, S., Barba, A., Gotti, E., Tessari, G., Schena, D., Diociaiuti, A., Nanni, G., Parola, I. L. L., et al. (2000) · Transplantation · doi:10.1097/00007890-200011270-00015 · Cited by 117
Schumacher, G., Oidtmann, M., Rosewicz, S., Langrehr, J. M., Jonas, S., Mueller, A., Rueggeberg, A., Neuhaus, R., Bahra, M., Jacob, D., et al. (2002) · Transplantation Proceedings · doi:10.1016/s0041-1345(02)02899-3 · Cited by 67
Rapamycin and tumor growth: mechanisms behind its anticancer activity
Koehl, G. E., Schlitt, H. J., & Geissler, E. K. (2005) · Transplantation Reviews · doi:10.1016/j.trre.2005.01.001 · Cited by 37
Cited by
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., Broeders, N., del Marmol, V., Chatelet, V., Dompmartin, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204166 · Cited by 593
Self-citationSchena, F. P., Pascoe, M. D., Alberu, J., del Carmen Rial, M., Oberbauer, R., Brennan, D. C., Campistol, J. M., Racusen, L., Polinsky, M. S., Goldberg-Alberts, R., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181927a41 · Cited by 583
Self-citationImmunosuppressive Therapy and Malignancy in Organ Transplant Recipients: A Systematic Review
Gutierrez-Dalmau, A., & Campistol, J. M. (2007) · Drugs · doi:10.2165/00003495-200767080-00006 · Cited by 408
Self-citationSkin cancer in solid organ transplant recipients: Advances in therapy and management
O’Reilly Zwald, F., & Brown, M. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.063 · Cited by 354
Metadata
- Authors
- Campistol, J. M., Eris, J., Oberbauer, R., Friend, P., Hutchison, B., Morales, J. M., Claesson, K., Stallone, G., Russ, G., Rostaing, L., Kreis, H., Burke, J. T., Brault, Y., Scarola, J. A., & Neylan, J. F.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2006-02
- Volume
- 17
- Issue
- 2
- Pages
- 581-589
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2119861401
- Cited by
- 478
- References
- 17
- FWCI
- 28.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.